Proteolysis Targeting Chimera (PROTAC) is a novel approach to modern drug development programs that utilizes small compounds to target proteins for ubiquitination and degradation by proteasome. 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(1-piperazinyl)propoxy]-3-quinolinecarbonitrile is a PROTAC compound, which has the potential to target oncogenic BCR-ABL for degradation. 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(1-piperazinyl)propoxy]-3-quinolinecarbonitrile has also been employed in ligand-based pharmacophore modelling to identify c-Src inhibitors.
